Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes

Karam Kostner; Stephen Nicholls; John Amerena; Alex Brown; Mark Cooper; Chris Hammett; Richard O'Brien; Leonard Kritharides; David L. Hare; Gerald F. Watts; Philip Aylward

doi:10.1016/j.hlc.2016.09.005

Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes

Karam Kostner
, Stephen Nicholls
, John Amerena
, Alex Brown
, Mark Cooper
, Chris Hammett
, Richard O'Brien
, Leonard Kritharides
, David L. Hare
, Gerald F. Watts
, Philip Aylward

College of Medicine and Public Health

Research output: Contribution to journal › Editorial

1 Citation (Scopus)

Abstract

There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.

Original language	English
Pages (from-to)	1051-1054
Number of pages	4
Journal	Heart, Lung and Circulation
Volume	25
Issue number	11
DOIs	https://doi.org/10.1016/j.hlc.2016.09.005
Publication status	Published - 1 Nov 2016

Keywords

Coronary Syndromes
intensive LDL reduction
improved outcomes
post acute

Access to Document

10.1016/j.hlc.2016.09.005Licence: In Copyright

Cite this

@article{efee2a1af9484c00a6a690b93552c1be,

title = "Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes",

abstract = "There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.",

keywords = "Coronary Syndromes, intensive LDL reduction, improved outcomes, post acute",

author = "Karam Kostner and Stephen Nicholls and John Amerena and Alex Brown and Mark Cooper and Chris Hammett and Richard O'Brien and Leonard Kritharides and Hare, \{David L.\} and Watts, \{Gerald F.\} and Philip Aylward",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.hlc.2016.09.005",

language = "English",

volume = "25",

pages = "1051--1054",

journal = "Heart, Lung and Circulation",

issn = "1443-9506",

publisher = "Elsevier Ltd.",

number = "11",

}

TY - JOUR

T1 - Intensive LDL Reduction Post Acute Coronary Syndromes

T2 - A Catalyst for Improved Outcomes

AU - Kostner, Karam

AU - Nicholls, Stephen

AU - Amerena, John

AU - Brown, Alex

AU - Cooper, Mark

AU - Hammett, Chris

AU - O'Brien, Richard

AU - Kritharides, Leonard

AU - Hare, David L.

AU - Watts, Gerald F.

AU - Aylward, Philip

PY - 2016/11/1

Y1 - 2016/11/1

N2 - There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.

AB - There is overwhelming evidence that intensive statin therapy reduces atherogenic lipoproteins as well as cardiovascular events post acute coronary syndromes (ACS) [1], [2]. Furthermore, post-hoc analyses from randomised trials show that the benefit of statin therapy depends on the extent of LDL reduction [3]; patients achieving very low LDL cholesterol (LDL-C) levels in statin trials are at very low cardiovascular (CV) risk [4] and show no increased risk of adverse events related to the achievement of very low LDL-C levels.

KW - Coronary Syndromes

KW - intensive LDL reduction

KW - improved outcomes

KW - post acute

UR - https://www.scopus.com/pages/publications/84991710750

U2 - 10.1016/j.hlc.2016.09.005

DO - 10.1016/j.hlc.2016.09.005

M3 - Editorial

C2 - 27725093

AN - SCOPUS:84991710750

SN - 1443-9506

VL - 25

SP - 1051

EP - 1054

JO - Heart, Lung and Circulation

JF - Heart, Lung and Circulation

IS - 11

ER -

Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this